Bulk Manufacturer of Controlled Substances Application: Sigma Aldrich Research Biochemicals, Inc., 19085-19086 [2017-08344]

Download as PDF 19085 Federal Register / Vol. 82, No. 78 / Tuesday, April 25, 2017 / Notices Controlled substance Drug code Codeine .......................................................................................................................................................................... Oxycodone ..................................................................................................................................................................... Hydromorphone ............................................................................................................................................................. Hydrocodone .................................................................................................................................................................. Methadone ..................................................................................................................................................................... Methadone intermediate ................................................................................................................................................ Dextropropoxyphene, bulk (non-dosage forms) ............................................................................................................ Morphine ........................................................................................................................................................................ Oripavine ........................................................................................................................................................................ Thebaine ........................................................................................................................................................................ Opium tincture ............................................................................................................................................................... Oxymorphone ................................................................................................................................................................ The company plans to manufacturer the listed controlled substances in bulk for distribution to its customers. Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before June 26, 2017. DATES: Dated: April 18, 2017. Louis J. Milione, Assistant Administrator. [FR Doc. 2017–08347 Filed 4–24–17; 8:45 am] Drug Enforcement Administration Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152. [Docket No. DEA–392] SUPPLEMENTARY INFORMATION: ADDRESSES: BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Bulk Manufacturer of Controlled Substances Application: Sigma Aldrich Research Biochemicals, Inc. ACTION: Notice of application. The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with asabaliauskas on DSK3SPTVN1PROD with NOTICES Drug code Cathinone ....................................................................................................................................................................... Methcathinone ............................................................................................................................................................... Mephedrone (4-Methyl-N-methylcathinone) .................................................................................................................. Aminorex ........................................................................................................................................................................ Alpha-ethyltryptamine .................................................................................................................................................... Lysergic acid diethylamide ............................................................................................................................................ Tetrahydrocannabinols .................................................................................................................................................. 4-Bromo-2,5-dimethoxyamphetamine ............................................................................................................................ 4-Bromo-2,5-dimethoxyphenethylamine ........................................................................................................................ 4-Methyl-2,5-dimethoxyamphetamine ............................................................................................................................ 2,5-Dimethoxyamphetamine .......................................................................................................................................... 3,4-Methylenedioxyamphetamine .................................................................................................................................. N-Hydroxy-3,4-methylenedioxyamphetamine ................................................................................................................ 3,4-Methylenedioxy-N-ethylamphetamine ..................................................................................................................... 3,4-Methylenedioxymethamphetamine .......................................................................................................................... Dimethyltryptamine ........................................................................................................................................................ Psilocybin ....................................................................................................................................................................... 5-Methoxy-N,N-diisopropyltryptamine ............................................................................................................................ 1-[1-(2-Thienyl)cyclohexyl]piperidine ............................................................................................................................. N-Benzylpiperazine ........................................................................................................................................................ MDPV (3,4-Methylenedioxypyrovalerone) ..................................................................................................................... Methylone (3,4-Methylenedioxy-N-methylcathinone) .................................................................................................... Heroin ............................................................................................................................................................................ Normorphine .................................................................................................................................................................. Norlevorphanol ............................................................................................................................................................... Amphetamine ................................................................................................................................................................. Methamphetamine ......................................................................................................................................................... Nabilone ......................................................................................................................................................................... 1-Phenylcyclohexylamine .............................................................................................................................................. Phencyclidine ................................................................................................................................................................. Cocaine .......................................................................................................................................................................... Codeine .......................................................................................................................................................................... Ecgonine ........................................................................................................................................................................ 17:42 Apr 24, 2017 Jkt 241001 PO 00000 Frm 00070 Fmt 4703 Sfmt 4703 II II II II II II II II II II II II respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (‘‘Assistant Administrator’’) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.33(a), this is notice that on December 19, 2016, Sigma Aldrich Research Biochemicals, Inc., 1–3 Strathmore Road, Natick, Massachusetts 01760–2447 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances: Controlled substance VerDate Sep<11>2014 9050 9143 9150 9193 9250 9254 9273 9300 9330 9333 9630 9652 Schedule E:\FR\FM\25APN1.SGM 25APN1 1235 1237 1248 1585 7249 7315 7370 7391 7392 7395 7396 7400 7402 7404 7405 7435 7437 7439 7470 7493 7535 7540 9200 9313 9634 1100 1105 7379 7460 7471 9041 9050 9180 Schedule I I I I I I I I I I I I I I I I I I I I I I I I I II II II II II II II II 19086 Federal Register / Vol. 82, No. 78 / Tuesday, April 25, 2017 / Notices Controlled substance Drug code Levomethorphan ............................................................................................................................................................ Levorphanol ................................................................................................................................................................... Meperidine ..................................................................................................................................................................... Metazocine ..................................................................................................................................................................... Methadone ..................................................................................................................................................................... Morphine ........................................................................................................................................................................ Thebaine ........................................................................................................................................................................ Levo-alphacetylmethadol ............................................................................................................................................... Remifentanil ................................................................................................................................................................... Sufentanil ....................................................................................................................................................................... Carfentanil ...................................................................................................................................................................... Fentanyl ......................................................................................................................................................................... The company plans to manufacture reference standards. Dated: April 18, 2017. Louis J. Milione, Assistant Administrator. [FR Doc. 2017–08344 Filed 4–24–17; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE [OMB Number 1121–0064] Agency Information Collection Activities; Proposed eCollection eComments Requested; Extension of a Currently Approved Collection: Annual Parole Survey, Annual Probation Survey Bureau of Justice Statistics, Department of Justice. ACTION: 60-Day notice. AGENCY: The Department of Justice (DOJ), Office of Justice Programs, Bureau of Justice Statistics, will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. DATES: Comments are encouraged and will be accepted for 60 days until June 26, 2017. FOR FURTHER INFORMATION CONTACT: If you have additional comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Danielle Kaeble, Statistician, Bureau of Justice Statistics, 810 Seventh Street NW., Washington, DC 20531 (email: Danielle.Kaeble@usdoj.gov; telephone: 202–305–2017). SUPPLEMENTARY INFORMATION: Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should asabaliauskas on DSK3SPTVN1PROD with NOTICES SUMMARY: VerDate Sep<11>2014 17:42 Apr 24, 2017 Jkt 241001 address one or more of the following four points: —Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the Bureau of Justice Statistics, including whether the information will have practical utility; —Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; —Evaluate whether and if so how the quality, utility, and clarity of the information to be collected can be enhanced; and —Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses. Overview of This Information Collection 1. Type of Information Collection: Extension of a currently approved collection. 2. The Title of the Form/Collection: Annual Parole Survey, Annual Probation Survey. 3. The agency form number, if any, and the applicable component of the Department sponsoring the collection: Form numbers for the questionnaire are CJ–7 Annual Parole Survey; CJ–8 Annual Probation Survey; CJ–8a Annual Probation Survey (Short Form). The applicable component within the Department of Justice is the Bureau of Justice Statistics, in the Office of Justice Programs. 4. Affected public who will be asked or required to respond, as well as a brief abstract: Primary: State departments of corrections or state probation and parole authorities. Others: The Federal Bureau of Prisons, city and county courts and PO 00000 Frm 00071 Fmt 4703 Sfmt 9990 9210 9220 9230 9240 9250 9300 9333 9648 9739 9740 9743 9801 Schedule II II II II II II II II II II II II probation offices for which a central reporting authority does not exist. For the CJ–7 form, the affected public consists of 53 respondents including 51 central reporters (two state respondents in Pennsylvania, and one each from the remaining states), the District of Columbia, and the Federal Bureau of Prisons responsible for keeping records on parolees. For the CJ–8 form, the affected public includes 305 reporters including 35 state respondents, the District of Columbia, the Federal Bureau of Prisons, and 268 from local authorities responsible for keeping records on probationers. For the CJ–8A form, the affected public includes 151 reporters who are all local authorities responsible for keeping records on probationers. The Annual Parole Survey and Annual Probation surveys have been used since 1977 to collect annual yearend counts and yearly movements of community corrections populations; characteristics of the community supervision population, such as gender, racial composition, ethnicity, conviction status, offense, and supervision status. 5. An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond: 509 respondents each taking an average of 1.63 hours to respond. 6. An estimate of the total public burden (in hours) associated with the collection: There is an estimated 830 total burden hours associated with this collection. If additional information is required contact: Melody Braswell, Department Clearance Officer, United States Department of Justice, Justice Management Division, Policy and Planning Staff, Two Constitution Square, 145 N Street NE., 3E.405A, Washington, DC 20530. Dated: April 20, 2017. Melody Braswell, Department Clearance Officer for PRA, U.S. Department of Justice. [FR Doc. 2017–08342 Filed 4–24–17; 8:45 am] BILLING CODE 4410–18–P E:\FR\FM\25APN1.SGM 25APN1

Agencies

[Federal Register Volume 82, Number 78 (Tuesday, April 25, 2017)]
[Notices]
[Pages 19085-19086]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-08344]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Bulk Manufacturer of Controlled Substances Application: Sigma 
Aldrich Research Biochemicals, Inc.

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic classes, and 
applicants therefore, may file written comments on or objections to the 
issuance of the proposed registration in accordance with 21 CFR 
1301.33(a) on or before June 26, 2017.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DRW, 
8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his 
authority under the Controlled Substances Act to the Administrator of 
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority 
to exercise all necessary functions with respect to the promulgation 
and implementation of 21 CFR part 1301, incident to the registration of 
manufacturers, distributors, dispensers, importers, and exporters of 
controlled substances (other than final orders in connection with 
suspension, denial, or revocation of registration) has been redelegated 
to the Assistant Administrator of the DEA Diversion Control Division 
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0, 
appendix to subpart R.
    In accordance with 21 CFR 1301.33(a), this is notice that on 
December 19, 2016, Sigma Aldrich Research Biochemicals, Inc., 1-3 
Strathmore Road, Natick, Massachusetts 01760-2447 applied to be 
registered as a bulk manufacturer of the following basic classes of 
controlled substances:

------------------------------------------------------------------------
        Controlled substance             Drug code         Schedule
------------------------------------------------------------------------
Cathinone...........................            1235  I
Methcathinone.......................            1237  I
Mephedrone (4-Methyl-N-                         1248  I
 methylcathinone).
Aminorex............................            1585  I
Alpha-ethyltryptamine...............            7249  I
Lysergic acid diethylamide..........            7315  I
Tetrahydrocannabinols...............            7370  I
4-Bromo-2,5-dimethoxyamphetamine....            7391  I
4-Bromo-2,5-dimethoxyphenethylamine.            7392  I
4-Methyl-2,5-dimethoxyamphetamine...            7395  I
2,5-Dimethoxyamphetamine............            7396  I
3,4-Methylenedioxyamphetamine.......            7400  I
N-Hydroxy-3,4-                                  7402  I
 methylenedioxyamphetamine.
3,4-Methylenedioxy-N-                           7404  I
 ethylamphetamine.
3,4-Methylenedioxymethamphetamine...            7405  I
Dimethyltryptamine..................            7435  I
Psilocybin..........................            7437  I
5-Methoxy-N,N-diisopropyltryptamine.            7439  I
1-[1-(2-                                        7470  I
 Thienyl)cyclohexyl]piperidine.
N-Benzylpiperazine..................            7493  I
MDPV (3,4-                                      7535  I
 Methylenedioxypyrovalerone).
Methylone (3,4-Methylenedioxy-N-                7540  I
 methylcathinone).
Heroin..............................            9200  I
Normorphine.........................            9313  I
Norlevorphanol......................            9634  I
Amphetamine.........................            1100  II
Methamphetamine.....................            1105  II
Nabilone............................            7379  II
1-Phenylcyclohexylamine.............            7460  II
Phencyclidine.......................            7471  II
Cocaine.............................            9041  II
Codeine.............................            9050  II
Ecgonine............................            9180  II

[[Page 19086]]

 
Levomethorphan......................            9210  II
Levorphanol.........................            9220  II
Meperidine..........................            9230  II
Metazocine..........................            9240  II
Methadone...........................            9250  II
Morphine............................            9300  II
Thebaine............................            9333  II
Levo-alphacetylmethadol.............            9648  II
Remifentanil........................            9739  II
Sufentanil..........................            9740  II
Carfentanil.........................            9743  II
Fentanyl............................            9801  II
------------------------------------------------------------------------

    The company plans to manufacture reference standards.

    Dated: April 18, 2017.
Louis J. Milione,
Assistant Administrator.
[FR Doc. 2017-08344 Filed 4-24-17; 8:45 am]
 BILLING CODE 4410-09-P